Home > Healthcare > Biotechnology > Bioservices > Oncology Based In-vivo CRO Market

Oncology Based In-vivo CRO Market Analysis

  • Report ID: GMI12605
  • Published Date: Dec 2024
  • Report Format: PDF

Oncology Based In-vivo CRO Market Analysis

Based on service, the market is segmented into preclinical testing, efficacy testing, toxicology studies, pharmacokinetics, and other services. Preclinical testing segment dominate the market with a share of 33.2% in 2024.
 

  • The preclinical testing segment leads the oncology-based in-vivo CRO market due to its pivotal role in the drug development process. Regulatory agencies, including the U.S. FDA and EMA, require preclinical testing before allowing clinical trials. This step guarantees the safety and efficacy of drug candidates prior to human testing. Preclinical studies provide crucial data on toxicity, pharmacokinetics, pharmacodynamics, and therapeutic potential, making them indispensable in the drug development pipeline.
     
  • Additionally, the growing number of oncology drug candidates in the pipeline has significantly increased the demand for preclinical testing. Small and large biotech and pharmaceutical companies are heavily investing in cancer therapies, particularly in areas like immuno-oncology and targeted therapies, further fueling the need for preclinical evaluation. According to an American Health and Drug Benefits study published by National Center for Biotechnology Information in December 2021, about oncology accounted for 75% of pharmaceutical research and development efforts.
     

Oncology Based In-vivo CRO Market, By Model (2024)

Based on model, the oncology based in-vivo CRO market is segmented into xenograft, syngeneic, other models. The xenograft is further sub-segmented as patient derived xenograft, cell-line derived xenograft, and other xenografts. The xenograft segment held a dominating share of 48.2% in the oncology-based in-vivo CRO market in 2024.
 

  • The crucial factors contributing to the leading share of xenograft are their unmatched ability to simulate human tumor biology and provide critical insights into cancer drug efficacy. Xenograft models involve implanting human tumor cells or tissues into immunocompromised mice, offering a more accurate representation of human cancer biology compared to other models.
     
  • Additionally, surge in immunotherapy research, such as immune checkpoint inhibitors and CAR-T cell therapies, has further surged the demand for xenograft models globally.
     
  • Moreover, as these models are derived directly from patient tumor tissues, they preserve the genetic, molecular, and histological characteristics of the original tumor, which supports the development of precision oncology drugs, contributing to the increased use of xenograft models.
     

Based on end user, the oncology based in-vivo CRO market is segmented into pharmaceutical companies, biotechnology companies, and other end users. The pharmaceutical companies segment dominated the market with a share of about 52.1% in the year 2024.
 

  • Pharmaceutical companies are increasingly dependent on CROs for continuous research and development, driven by the substantial revenue generated from cancer drugs. As a result, these companies have become the primary end-users of oncology in-vivo CRO services. According to a January 2022 study published by National Center for Biotechnology Information, over the past decade, the top 10 global pharmaceutical companies have experienced a 70% surge in cancer drug sales revenues.
     
  • Pharmaceutical companies are increasingly adopting multi-drug regimens, which require comprehensive in-vivo testing to evaluate efficacy, toxicity, and pharmacokinetics. In-vivo CROs, with their specialized capabilities in combination therapy assessments, have become vital partners for these companies.
     

U.S. Oncology Based In-vivo CRO Market, 2021 – 2034 (USD Million)

In 2024, the U.S. led the North American oncology based in-vivo CRO market, generating a revenue of about USD 509 million.
 

  • The leading share of the country can be primarily attributed to significant investments in cancer research, and strong presence of pharmaceutical and biotechnology companies. For instance, according to the American Society of Clinical Oncology, NIH invests about USD 65 billion in cancer-based research each year in the U.S.
     
  • Moreover, The U.S. is home to leading companies such as Pfizer, Merck, Bristol-Myers Squibb, and Amgen, which are heavily invested in oncology drug development. These companies outsource preclinical and in-vivo studies to CROs, driving demand for advanced in-vivo testing services.
     
  • Additionally, FDA's accelerated approval pathways and orphan drug designation to many pipelines under clinical stages have boosted the availability of oncology therapies for rare cancers in the U.S., driving the demand for preclinical studies and pharmacokinetics in the country.
     

The UK is set to see a robust expansion in its oncology based in-vivo CRO market from 2025 to 2034.
 

  • Increasing incidence of cancer is driving the demand for advanced cancer therapies, further contributing to an increased demand for oncology-based in-vivo studies across CROs in the country. According to Cancer Research UK, each year, the UK witnesses over 385,000 new cancer diagnoses.
     
  • Further, the UK has some of the world’s leading research institutions, such as the University of Oxford, University of Cambridge, and The Institute of Cancer Research. The presence of these esteemed research institutions together with growing investment in research and development for new oncology therapies is driving the revenue growth in UK oncology-based in-vivo CRO market.
     
  • For instance, according to the UK Research and Innovation (UKRI), in October 2024, Innovate UK and the Office for Life Sciences (OLS) have announced additional funding to support innovation in cancer treatment. As part of the advancing precision medicines competition, Innovate UK and OLS will invest USD 4.2 million in six projects. This funding aligns with the Life Sciences Vision Cancer Mission. This announcement follows a 2023 initiative where seven cancer projects received a total of USD 4.73 million.
     

Japan's oncology based in-vivo CRO market is set for lucrative growth from 2025 to 2034.
 

  • Growing support from government initiatives for cancer research to address the country's aging population and increasing cancer incidence is driving the Japan's oncology-based in-vivo CRO market. For instance, in April 2021, the US and Japan governments launched the US-Japan CoRe Partnership, emphasizing their continued collaboration in cancer research.
     
  • Moreover, Japan has been at the forefront of developing immuno-oncology therapies, such as immune checkpoint inhibitors and cancer vaccines, which require extensive preclinical testing using in-vivo models. For instance, in February 2024, ONO secured supplemental approval in Japan for an expanded indication of Opdivo, targeting the treatment of unresectable advanced or recurrent malignant epithelial tumours.
     

Saudi Arabia's oncology based in-vivo CRO market is expected to witness substantial growth during the forecast period.
 

  • Saudi Arabia is fostering a burgeoning biotech sector with a focus on oncology. Biotech startups in the region are developing innovative cancer therapies that necessitate advanced preclinical testing. Many of these companies outsource to CROs with specialized expertise in in-vivo models.
     
  • Regulatory authorities, such as the Saudi Food and Drug Authority (SFDA), play a crucial role in regulating and supporting oncology drug development in Saudi Arabia. The SFDA's alignment with international standards, including those of the U.S. FDA and EMA, has facilitated the approval of oncology drugs and emphasized the necessity for rigorous preclinical testing, including in-vivo studies.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global oncology-based in-vivo CRO industry was valued at USD 1.4 billion in 2024 and is projected to grow at an 8.8% CAGR from 2025 to 2034, driven by the increasing demand for immuno-oncology therapies.

The preclinical testing segment held a 33.2% market share in 2024 due to its essential role in the drug development process, mandated by regulatory agencies like the U.S. FDA and EMA.

The U.S. led the North American oncology-based in-vivo CRO market in 2024, generating approximately USD 509 million, primarily due to significant investments in cancer research and a strong presence of pharmaceutical and biotechnology companies.

Key players in the market include Charles River Laboratories, Crown Bioscience, Eurofins Scientific, Evotec SE, ICON plc, IMV, Laboratory Corporation of America Holdings, Medidata, Merck KGaA, OncoOne, Pharmaron, and Taconic Biosciences.

Oncology Based In-vivo CRO Market Scope

Buy Now


Premium Report Details

  • Base Year: 2024
  • Companies covered: 15
  • Tables & Figures: 123
  • Countries covered: 18
  • Pages: 140
 Download Free Sample